Home » JERINI REPORTS INCREASE IN REVENUES FOR THIRD QUARTER AND FOR THE FIRST NINE MONTHS
JERINI REPORTS INCREASE IN REVENUES FOR THIRD QUARTER AND FOR THE FIRST NINE MONTHS
The Berlin-based pharmaceutical company Jerini AG (FSE:JI4) reported a 47 percent
increase in its third quarter revenues to EUR 2.5 million from EUR 1.7 for the
same period in 2004. The G&A expense increased to EUR 2.4 million compared
to EUR 0.8 million as a result of the expansion in the investor relations and
marketing departments. The loss from operations (EBIT) in the third quarter
amounted to (EUR 4.2 million) compared to (EUR 3.0 million) for the third quarter
2004.
Biotech
Intelligence
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May